arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

GERON CORP

GERN
$0.95 ▼ -0.12 (-11.63%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
68 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
38
Health
Weak
Bearish
auto_awesome

Analytical Summary

GERON CORP faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap —
Dividend Yield —
Revenue Growth 17.2% ↘
Op. Margin -21.7% ↘
ROIC -2.9% ↘
FCF / Share $-23.60 ↗
Trailing P/E —
Price / Book —
FCF Yield —
Debt / Equity 0.55
info Valuation on last close. End-of-day price, Nov 5, 2026.

68-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$57.48M
↑ +17.2% —
Net Income Profit after all expenses
$-3.64M
↑ +81.6% —
Operating Margin Operating profit as % of sales
-21.7%
↓ -7232.4% —
FCF / Share Free cash flow per share
$-23.60
↑ +74.9% —
Long-Term Debt Long-term obligations
$120.13M
— +0.2% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↑
20
Financial Health ↑
42
Cash Quality ↑
77

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 18 years · 68 quarters